CD19 and neoplasm: In preclinical models for treating pediatric rhabdomyosarcoma with FGFR4 and CD276, and B-ALL with CD19/CD20, dual CARs with diverse co-stimulatory domains (CD28 and 4-1BB) showed better persistence and anti-tumor activity than dual CARs with the same co-stimulatory domains [71,80].